MSH6 and breast cancer: Regarding the clinical impact of the genetic variants identified in this study, we found that the risk of having a pathogenic or VUS variant in MSH6 was reduced by 94% in patients ER + BC (p = 0.004) and 88% in patients PR + BC (p = 0.025) and this significant effect was maintained for age-adjustments.